首页>投融资

Fog Pharma

E~PreIPO

Fog Pharmaceuticals, doing business as FogPharma, is a biopharmaceutical company focused on developing helicon polypeptide-based therapeutics for the potential treatment of cancer.In November 2022, the company announced a USD 178 Million Series D financing.In March 2021, the company announced USD 107 million in Series C financing.In May 2018, the company raised gross proceeds of USD 66 million in closing of Series B financing

https://fogpharma.com/

470211

基本信息

公司全称

Fog Pharmaceuticals Inc
类型

抗癌新药研发商
产业领域

医药研发/制造、化学&生物药
公司人数

15~50人
地址

30 Acorn Park Drive 6th Floor CAMBRIDGE MASSACHUSETTS 02140; US; Telephone: +16179459510;
联系电话

617-945-9510
邮箱

info@fogpharma.com
成立时间

2015-01-01

投融资

2024-03-01

E~PreIPO

1.45亿美元

Nextech Invest

ARCH Venture Partners

富达国际

GV

鱼鹰资管

T. Rowe Price

Farallon Capital Management

VenBio Partners

Invus

Milky Way Investments

Sixty Degree Capital

Catalio Capital Management

Symbiosis

Foresite Capital

Samsara BioCapital

Marshall Wace

General Catalyst

Rock Springs Capital

RA Capital
2022-11-21

D轮

1.78亿美元

GV

Farallon Capital Management

Invus

Casdin Capital

HBM Healthcare

ARCH Venture Partners

Deerfield

Pagsgroup

鱼鹰资管

Milky Way Investments

VenBio Partners

T. Rowe Price

富达国际
2021-03-01

C轮

1.07亿美元

VenBio Partners

蓝池资本（Blue Pool Capital）

Deerfield

通和毓承

GV

Pagsgroup

Casdin Capital

HBM Healthcare

T. Rowe Price

Invus

Farallon Capital Management

鱼鹰资管
2018-05-16

B轮

6600万美元

通和毓承

Horizons Ventures

GV

蓝池资本（Blue Pool Capital）
加载更多

Fog Pharma

基本信息

投融资

相关投融资企业